$SYRE earnings report

Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update. AlphAI read Spyre Therapeutics's Third Quarter 2026 filing as mixed. 2 quarters are on record below.

Third Quarter 2026

AlphAI · Earnings readSYRE · Third Quarter 2026 · ended September 30, 2026

Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

→Mixed quarter

The company reported completed proof-of-concept across its three IBD monotherapies and accelerated enrollment in SKYLINE Part B, while discontinuing SPY072 development in rheumatic diseases after PsA and axSpA sub-studies did not meet primary endpoints. Cash resources were strengthened by the October financing, but quarterly R&D expense and net loss increased year over year.

EPS · GAAP
$(0.94)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Research and development expenses, three months ended September 30, 2026GAAP$89.2M––
General and administrative expenses, three months ended September 30, 2026GAAP$16.6M––
Total operating expenses, three months ended September 30, 2026GAAP$105.7M––
Loss from operations, three months ended September 30, 2026GAAP−$105.7M––
Interest income, three months ended September 30, 2026GAAP$10.63M––
Other income, three months ended September 30, 2026GAAP$9.6M––
Net loss, three months ended September 30, 2026GAAP$96.1M––
Net loss per share, basic and diluted, common, three months ended September 30, 2026GAAP$(0.94)––
Net loss per share, basic and diluted, Series A Preferred Stock, three months ended September 30, 2026GAAP$(37.60)––
Weighted-average common stock outstanding, basic and diluted, three months ended September 30, 2026GAAP88,410,821––
Research and development expenses, nine months ended September 30, 2026GAAP$215.1M––
General and administrative expenses, nine months ended September 30, 2026GAAP$47.92M––
Gain on sale of in-process research and development asset, nine months ended September 30, 2026GAAP−$70M––
Total operating expenses, nine months ended September 30, 2026GAAP$193.0M––
Loss from operations, nine months ended September 30, 2026GAAP−$193.0M––
Total other income (expense), nine months ended September 30, 2026GAAP−$8.33M––
Net loss, nine months ended September 30, 2026GAAP−$201.3M––
Net loss per share, basic and diluted, common, nine months ended September 30, 2026GAAP$(2.04)––
Cash and cash equivalents, September 30, 2026GAAP$82.73M––
Marketable securities, September 30, 2026GAAP$989.2M––
Total assets, September 30, 2026GAAP$1.10B––
Total liabilities, September 30, 2026GAAP$48.19M––
Total stockholders' equity, September 30, 2026GAAP$1.05B––

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Second half of 2029 and clinical milestones in 2027 and 2028 outlook

  • NoteExpected runway into the second half of 2029
  • NoteSKYLINE Part B induction data expected in the third quarter of 2027
  • NoteSKYLIGHT topline Week 16 results planned in late 2027 or early 2028
  • NoteThe Company plans to advance a potential best-in-class anti-TL1A monotherapy agent into pivotal studies for HS in 2027

What drove it

  • R&D expense increased primarily due to higher manufacturing costs and clinical trial expenses.
  • G&A expense increased primarily due to increased headcount and professional services fees.
  • The change in other income was primarily due to changes in the fair value of the contingent value right liability in the prior period.
  • SKYLINE Part B is enrolling ahead of schedule, enabling an increased enrollment target.
  • SPY001, SPY002, and SPY003 each achieved their respective primary endpoints in SKYLINE Part A and were well tolerated with a safety profile consistent with in-class comparators.
  • The company initiated the SKYLIGHT Phase 2 trial of SPY072 in HS in September 2026.

Concerns

  • SPY072 will not be advanced in rheumatic disease after the PsA and axSpA SKYWAY sub-studies did not meet their primary endpoints.
  • Although SPY072 demonstrated clinical activity in RA, the results did not meet the company's internal bar to prioritize advancement in RA.
  • Net loss totaled $96.1 million for the third quarter of 2026, compared with $11.2 million for the third quarter of 2025.
  • R&D expenses totaled $89.2 million for the third quarter of 2026, compared with $45.2 million for the third quarter of 2025.
  • SKYLINE combination induction data are not expected until the third quarter of 2027.

What to watch

  • Topline induction results from SKYLINE Part B for the SPY120, SPY130, and SPY230 combinations, expected in the third quarter of 2027.
  • Execution against the increased SKYLINE Part B enrollment target.
  • SKYLIGHT Phase 2 topline Week 16 results, planned in late 2027 or early 2028.
  • Planned advancement of SPY072 into pivotal HS monotherapy studies in 2027.
  • Cash runway expected into the second half of 2029.

Balance sheet and cash flow

  • Cash, cash equivalents, and marketable securities of $1,071.9 million as of September 30, 2026.
  • Pro forma cash of $1,467.9 million as of September 30, 2026.
  • Net cash used in operating activities was $77.5 million for the third quarter of 2026.
  • $378.0 million in net proceeds from the recently closed October 2026 underwritten public offering of common stock.
  • $18.0 million in October 2026 at-the-market (ATM) sales.
  • Total current liabilities were $40,143 (in thousands) as of September 30, 2026.
  • Non-current CVR liability was $6,760 (in thousands) as of September 30, 2026. No debt was reported in the balance sheet provided.

Analysis

Spyre reported a clinical and financing update alongside third-quarter results. The principal positive development was completion of proof-of-concept for all three IBD monotherapies after positive SPY003 induction data from SKYLINE Part A. The company stated that SPY001, SPY002, and SPY003 each achieved their respective primary endpoints and were well tolerated. SKYLINE Part B, which is evaluating monotherapies and combinations, is enrolling ahead of schedule and has an increased enrollment target, with induction data expected in the third quarter of 2027.

The rheumatology program produced a clear negative portfolio decision. SPY072 showed statistically significant benefits on one or more endpoints in the RA sub-study, but the company said the magnitude of benefit did not meet its internal bar for prioritization. In PsA and axSpA, SPY072 was well tolerated but neither sub-study met its primary endpoint. Spyre therefore does not plan to advance SPY072 in rheumatic diseases, while repositioning the asset for HS as monotherapy and in combination with IL-17A/F inhibition.

The income statement reflects increased development activity. Third-quarter R&D expenses were $89.2 million versus $45.2 million in the prior-year quarter, driven primarily by manufacturing costs and clinical trial expenses. G&A expenses were $16.6 million versus $11.6 million. Net loss was $96.1 million, compared with $11.2 million, while other income declined to $9.6 million from $45.7 million because the prior period included changes in the fair value of the CVR liability.

Liquidity was materially reinforced after quarter end. Spyre reported $1,071.9 million of cash, cash equivalents, and marketable securities as of September 30, 2026, and pro forma cash of $1,467.9 million after reflecting $378.0 million of net offering proceeds and $18.0 million of ATM sales in October. The company expects this capital to fund operations into the second half of 2029. The next major operating milestones are SKYLINE combination induction data in the third quarter of 2027 and SKYLIGHT Week 16 data in late 2027 or early 2028.

Management, verbatim

We are increasingly well-positioned to deliver on our ambition of elevating the standard of care across immunology. In IBD, our three compelling Phase 2 monotherapy readouts and a growing body of supportive clinical evidence strengthen our conviction that our combination products have the potential to transform the treatment paradigm.

Cameron Turtle, DPhil, Chief Executive Officer of Spyre

The combination portion of our SKYLINE trial is enrolling faster than expected enabling an increased enrollment target, and we plan to deliver topline data in Q3 2027 with the potential for efficacy, safety, and convenience that meaningfully surpasses today's standard of care.

Cameron Turtle, DPhil, Chief Executive Officer of Spyre

Not in the filing

stated, not guessed
  • Total revenue was not reported.
  • Revenue by segment was not reported.
  • Gross profit and gross margin were not reported.
  • Non-GAAP financial measures, including non-GAAP operating income and non-GAAP EPS, were not reported.
  • Free cash flow was not reported.
  • Debt balances were not reported.
  • Share repurchases and dividends were not reported.
  • Formal revenue, gross-margin, operating-expense, or tax-rate guidance was not reported.
  • Prior-quarter comparisons for the reported operating results were not reported.
  • Nothing comparable: the prior outlook is for milestones and cash runway, and the release reports only Q3 financial results with no matching guided metric.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second quarter 2026

AlphAI · Earnings readSYRE · Second quarter 2026 · ended June 30, 2026

Spyre Therapeutics reported second quarter 2026 results, highlighted positive SPY001 and SPY002 Phase 2 induction data, completed enrollment in all SKYWAY sub-studies, and reported cash runway into the second half of 2029.

✓Solid quarter

The company reported positive Phase 2 induction data for SPY001 and SPY002, completed enrollment across the three SKYWAY sub-studies, and held $1,145.3 million in cash, cash equivalents, and marketable securities. The period also included a $36.2 million net loss and $69.9 million of net cash used in operating activities.

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Cash, cash equivalents, and marketable securitiesGAAP$1.15B––
Net proceeds from public offering of common stockGAAP$435.2M––
Net cash used in operating activitiesGAAP$69.9M––
Research and development expensesGAAP$65.5M––
General and administrative expensesGAAP$16.1M––
Gain on sale of in-process research and development assetGAAP$40M––
Other incomeGAAP$5.4M––
Net lossGAAP$36.2M––
SPY001 reduction in Robart’s Histopathology Index scoreother9.2 points––
SPY002 reduction in Robart’s Histopathology Index scoreother10.7 points––
SPY001 clinical remission rateother40%––
SPY001 endoscopic improvement rateother51%––
SPY002 clinical remission rateother33%––
SPY002 endoscopic improvement rateother42%––
SPY001 and SPY002 change in modified Mayo Score from baseline at Week 12other-3.7––

2026 outlook

  • NoteRemain on track for 6 proof-of-concept Phase 2 readouts in 2026.
  • NoteTopline data expected for SPY003 in September 2026.
  • NoteTopline proof-of-concept data are expected in September 2026 for the RA sub-study.
  • NoteTopline proof-of-concept data are expected in the fourth quarter of 2026 for the PsA sub-study.
  • NoteTopline proof-of-concept data are expected in the fourth quarter of 2026 for the axSpA sub-study.
  • NoteInduction data expected in 2027 for Part B of the SKYLINE trial.
  • NoteExpected runway into the second half of 2029.

What drove it

  • R&D expenses increased primarily due to higher manufacturing and clinical trial expenses, as well as higher headcount costs.
  • G&A expenses increased primarily due to higher headcount costs.
  • The Company recognized a gain of $40.0 million for an achieved milestone related to Immedica’s sale of a priority review voucher.
  • SPY001 and SPY002 achieved their respective primary endpoints and were well-tolerated with a safety profile consistent with in-class comparators.
  • All three SKYWAY sub-studies completed enrollment on or ahead of schedule.

Concerns

  • Spyre remained a clinical-stage biotechnology company and reported a net loss of $36.2 million.
  • Net cash used in operating activities was $69.9 million for the second quarter of 2026.
  • R&D expenses totaled $65.5 million, with higher manufacturing, clinical trial, and headcount costs.
  • The pivotal upcoming program milestones remain clinical data readouts, including the RA sub-study, SPY003, PsA, and axSpA results.

What to watch

  • SPY072 RA sub-study topline proof-of-concept data expected in September 2026.
  • SPY003 Part A topline data from SKYLINE expected in September 2026.
  • SPY072 PsA and axSpA sub-study topline proof-of-concept data expected in the fourth quarter of 2026.
  • SKYLINE Part B enrollment progress and induction data expected in 2027.
  • Execution toward 6 proof-of-concept Phase 2 readouts in 2026.

Balance sheet and cash flow

  • Cash, cash equivalents, and marketable securities of $1,145.3 million as of June 30, 2026.
  • In April 2026, the Company raised $435.2 million in net proceeds from a public offering of common stock.
  • Net cash used in operating activities was $69.9 million for the second quarter of 2026.
  • Expected runway into the second half of 2029.

Analysis

Spyre’s second quarter update centered on clinical execution rather than commercial revenue. The company reported positive topline induction data from Part A of the SKYLINE Phase 2 trial for SPY001 and SPY002 in ulcerative colitis. Both agents achieved their respective primary endpoints, with reductions in the Robart’s Histopathology Index score of 9.2 points for SPY001 and 10.7 points for SPY002. Reported clinical remission and endoscopic improvement rates were 40% and 51%, respectively, for SPY001, and 33% and 42%, respectively, for SPY002.

The development cadence advanced during the quarter. Enrollment for Part A of SKYLINE has completed, SPY003 Part A data are expected in September 2026, and the company is enrolling monotherapies and combinations in Part B. All three SKYWAY sub-studies in RA, PsA, and axSpA completed enrollment on or ahead of schedule. The next scheduled data events are the RA sub-study and SPY003 in September 2026, followed by PsA and axSpA results in the fourth quarter of 2026.

Operating spending rose as the clinical pipeline advanced. R&D expenses totaled $65.5 million for the second quarter of 2026 versus $40.1 million for the second quarter of 2025, driven primarily by higher manufacturing and clinical trial expenses and higher headcount costs. G&A expenses totaled $16.1 million versus $11.8 million, primarily due to higher headcount costs. Net cash used in operating activities was $69.9 million, while net loss totaled $36.2 million compared with $36.7 million in the second quarter of 2025.

The reported net loss included a $40.0 million gain tied to an achieved milestone from the 2023 sale of global rights to pegzilarginase, specifically Immedica’s sale of a priority review voucher. Other income totaled $5.4 million compared with $5.2 million in the prior-year quarter. The company also raised $435.2 million in net proceeds from a public offering of common stock in April 2026.

Liquidity is the principal financial support for the planned clinical catalyst schedule. Spyre ended June 30, 2026 with $1,145.3 million of cash, cash equivalents, and marketable securities and stated that it expects runway into the second half of 2029. The filing provided no revenue, margin, EPS, or conventional financial outlook, so the near-term read is driven by the pending proof-of-concept clinical data and continued spending required to advance the SKYLINE and SKYWAY programs.

Management, verbatim

Following encouraging Phase 2 results from both SPY001 and SPY002, as well as competitor results validating the promise of combination therapy, the case for our approach in IBD has strengthened considerably. We believe our three investigational combinations have the potential to deliver efficacy, safety, and convenience beyond what is achievable with today’s therapies.

Cameron Turtle, DPhil, Chief Executive Officer of Spyre

Beyond IBD, we are approaching a pivotal milestone with placebo-controlled Phase 2 proof-of-concept data for SPY072, an anti-TL1A monotherapy, in rheumatoid arthritis expected next month, representing a key opportunity to demonstrate the broader utility of this mechanism. If successful, we look forward to initiating pivotal development of SPY072 next year, while also exploring combination approaches outside IBD.

Cameron Turtle, DPhil, Chief Executive Officer of Spyre

Not in the filing

stated, not guessed
  • Revenue and revenue comparisons were not reported.
  • Segment revenue and segment revenue comparisons were not reported.
  • Gross profit, gross margin, and gross-margin guidance were not reported.
  • Operating income or loss and operating-margin figures were not reported.
  • Earnings per share, diluted share count, and non-GAAP financial measures were not reported.
  • Free cash flow was not reported.
  • Debt was not reported.
  • Share repurchases and dividends were not reported.
  • Prior-quarter comparisons for reported financial metrics were not reported.
  • Financial revenue, operating-expense, gross-margin, and tax-rate guidance were not reported.
  • A previous outlook section was not provided.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about SYRE earnings dates

When is Spyre Therapeutics's next earnings date?
AlphAI has no date for SYRE yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.